Australia Markets closed

Zealand Pharma A/S (ZEAL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.09-0.16 (-1.56%)
At close: 01:03PM EDT
10.14 +0.05 (+0.50%)
Pre-market: 04:29AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.08
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 334.30
52-week low 39.98
50-day moving average 313.16
200-day moving average 322.20

Share statistics

Avg vol (3-month) 36.6k
Avg vol (10-day) 35.23k
Shares outstanding 543.22M
Implied shares outstanding 6N/A
Float 835.85M
% held by insiders 10.00%
% held by institutions 11.84%
Shares short (30 Dec 2021) 4165.84k
Short ratio (30 Dec 2021) 421.83
Short % of float (30 Dec 2021) 4N/A
Short % of shares outstanding (30 Dec 2021) 40.38%
Shares short (prior month 29 Nov 2021) 4131.16k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in DKK.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-359.62%

Management effectiveness

Return on assets (ttm)-36.48%
Return on equity (ttm)-80.59%

Income statement

Revenue (ttm)301.91M
Revenue per share (ttm)7.15
Quarterly revenue growth (yoy)88.20%
Gross profit (ttm)262.75M
EBITDA -1.08B
Net income avi to common (ttm)-1.12B
Diluted EPS (ttm)-4.03
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.05B
Total cash per share (mrq)24.3
Total debt (mrq)142.03M
Total debt/equity (mrq)11.98
Current ratio (mrq)4.23
Book value per share (mrq)27.47

Cash flow statement

Operating cash flow (ttm)-1.2B
Levered free cash flow (ttm)-695.47M